T

he European Commission has opened a formal investigation into Aspen Pharma over allegations the drug maker engaged in price gouging for five life-saving cancer medicines, marking the first EC probe into excessive pricing in the pharmaceutical industry.

The move, which was urged last month by consumer advocacy groups in Europe, comes after Italian antitrust authorities last October fined the drug maker $5.5 million for halting supplies of several cancer drugs as a negotiating tactic designed to boost prices by as much as 1,500 percent.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Please stop sending me messages.. Seeing as I am not a member and never will be. Thank you very much and have a nice day!

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X